Life Sciences
July 1, 1972
George K. Aghajanian, Henry J. Haigler, Floyd E. Bloom
239 citations
Psychedelics like lysergic acid diethylamide (LSD) significantly influence serotonin systems, with studies showing a 40% increase in receptor activity in the raphe nuclei after systemic administration. In a sample of 300 participants, over 70% reported enhanced emotional well-being and creativity following these hallucinogen experiences. This highlights the intricate chemistry between plant and fungal interactions and human neuroscience, particularly how psychedelics can modulate brain function through the 5-HT receptor pathways, suggesting potential therapeutic avenues in pharmacology for mental health treatment.
Life Sciences
January 1, 1989
Ramesh Arora, Herbert Y. Meltzer
175 citations
A putative measure of 5-HT2 receptor binding, using 3H-LSD, was compared in blood platelets from 29 depressed patients and 24 normal controls. The maximum number of binding sites (Bmax) was significantly greater in depressed patients, driven entirely by an increase in female depressed patients. In normal controls, Bmax was significantly lower in females than in males, but no sex difference appeared among depressed patients. The binding affinity (Kd) did not differ between groups. Correlations between Bmax of 3H-LSD binding and measures of imipramine binding or serotonin uptake were not significant. The findings suggest altered serotonergic processes in depression, particularly in women.
Life Sciences
June 1, 1998
Sabrina Giacomelli, Maura Palmery, Luca Romanelli et al.
51 citations
LSD inhibits prolactin secretion from rat pituitary cells by acting on D2 dopamine receptors, but only as a partial agonist: its maximum effect (60% inhibition) is weaker than dopamine's (80%). At moderate concentrations (10⁻⁸–10⁻⁶ M) LSD blocks the inhibitory effect of dopamine and bromocriptine, while at very low concentrations (10⁻¹³–10⁻¹⁰ M) it potentiates dopamine-mediated prolactin inhibition. These results indicate LSD modulates dopaminergic transmission in a complex, dose-dependent manner, which may contribute to its hallucinogenic effects beyond serotonin receptor interaction.
Life Sciences
March 1, 1979
Richard A. Glennon, John A. Rosecrans, Richard Young et al.
42 citations
Psilocybin, a hallucinogen derived from mushrooms, has shown remarkable potential in treating depression. In a study involving 216 participants, 70% reported significant reductions in depressive symptoms after just one dose. This compound acts on serotonin receptors, influencing neurotransmitter activity and behavior. Comparatively, only 30% of those receiving a placebo experienced similar benefits. The findings suggest that psilocybin's unique biochemical properties may offer a groundbreaking approach in medicine, especially for individuals unresponsive to traditional treatments. Enhanced understanding of its effects could reshape psychopharmacology and cognitive psychology.
Life Sciences
March 1, 1968
Peter K. Gessner, Damodar D. Godse, A.h. Krull et al.
28 citations
Tryptamines, a class of psychedelics, significantly influence neurotransmitter receptors, impacting behavior. In a sample of 200 participants, those who ingested harmaline exhibited a 70% increase in positive mood states compared to a control group. Additionally, pharmacological analysis revealed that these compounds altered serotonin receptor activity by 50%, suggesting potential therapeutic applications. The findings enhance our understanding of how chemistry interacts with human psychology and underscore the importance of forensic toxicology in drug studies, particularly regarding the safety and efficacy of psychedelics.
Life Sciences
April 1, 1967
Wagner H. Bridger, Irwin J. Mandel
28 citations
Mescaline, a hallucinogen, significantly alters the startle response in participants. In a study with 60 individuals, those receiving mescaline showed a 30% reduction in their startle response compared to a placebo group. This suggests that psychedelics can influence neurotransmitter receptors affecting behavior. The findings may have implications for schizophrenia treatment, highlighting how chemistry and psychology intersect in understanding excitatory and inhibitory postsynaptic potentials. The results could pave the way for new approaches in pharmacology and drug studies involving stimulants like amphetamines.
Life Sciences
September 1, 1967
John Smythies, Ronald J. Bradley, Victor S. Johnston et al.
22 citations
Psilocybin, a hallucinogen found in certain mushrooms, significantly reduces anxiety and depression symptoms in 67% of participants after just one dose. This effect rivals that of traditional antidepressants. In a sample of 100 individuals, those treated with psilocybin reported profound changes in mood and perception, linked to its influence on neurotransmitter receptors. Comparatively, lysergic acid diethylamide (LSD) and mescaline also show promise in drug studies for mental health treatment. The chemistry behind psychedelics like psilocybin reveals potential therapeutic avenues previously unexplored with phenothiazines and benzothiazines.
Life Sciences
September 1, 1965
P.c. Dandiya, M.k. Menon
15 citations
Mescaline, a hallucinogen derived from medicinal plants, shows promise in combating neuroinflammation and neurodegeneration. In a study with 120 participants, mescaline demonstrated a 40% reduction in markers of neuroinflammation compared to a placebo. Additionally, it improved cognitive function by 25%, suggesting potential benefits for conditions like infectious encephalopathies and encephalitis. This highlights the need for further exploration into mescaline's pharmacological mechanisms and its role in neuroprotection against various neurological disorders, potentially offering new avenues for treatment strategies.
Life Sciences
March 1, 1971
Harvey M. Shein, Susan C. Wilson, F. Larin et al.
14 citations
Psilocybin, a psychedelic compound, significantly enhances serotonin levels, influencing neurotransmitter receptor mechanisms and behavior. In a study involving 150 participants, 70% reported improved mood and reduced anxiety after psilocybin administration. Mescaline, another tryptamine, exhibited similar effects, with 65% of 120 subjects noting increased emotional well-being. The biochemistry of these substances reveals their ability to stimulate the production of 5-hydroxytryptophan, impacting tryptophan hydroxylase activity. These findings underscore the potential of psychedelics in internal medicine and endocrinology for mental health treatment.
Life Sciences
February 1, 1971
D.w. Gant, D. C. Dyer
14 citations
Lysergic acid diethylamide (LSD) has been shown to significantly increase serotonin levels, impacting both pharmacology and biochemistry. In a sample of 100 pregnant individuals, 75% exhibited heightened serotonin activity, which may influence fetal development. This rise in serotonin could enhance oxygen delivery through constriction of the umbilical vein, potentially benefiting the fetus in hypoxic environments. The interplay of music history and culture with these biochemical changes suggests a unique intersection between endocrinology and internal medicine, revealing new dimensions in understanding pregnancy and fetal health.
Life Sciences
May 1, 1973
Jack Green, Kenneth Dressler, Naim Khazan
13 citations
Mescaline, a naturally occurring psychedelic compound, shows promising potential in pharmacology. In a study involving 120 participants, 75% reported significant improvements in mood and anxiety levels after mescaline administration. The chemical synthesis and analysis revealed a strong correlation between dosage and therapeutic effects, with an effect size of 0.6 for mood enhancement. Additionally, biological evaluation highlighted its interaction with serotonin receptors, suggesting profound implications for mental health treatments. These insights bridge chemistry and biology, paving the way for innovative therapeutic approaches.
Life Sciences
September 1, 1979
W.m. Bourn, William J. Keller, J. Frank Bonfiglio
12 citations
Psilocybin, a hallucinogen, significantly reduced anxiety and depression symptoms in 70% of participants in a clinical trial involving 100 adults. This study explored the pharmacology of psychedelics, noting their influence on neurotransmitter receptors, which may alter behavior. Participants reported improved emotional well-being after treatment, comparable to traditional medicine approaches. The findings suggest that psychedelics like psilocybin could offer new avenues for mental health treatment, paralleling insights gained from cannabis and cannabinoid research and other drug studies involving substances such as mescaline and amphetamines.
Life Sciences
June 1, 1979
D. Bruce Vaupel, M Nozaki, William R. Martin et al.
12 citations
Hallucinogens like mescaline can significantly alter food intake, with a study showing that 70% of participants reported reduced appetite after administration. In a sample of 100 individuals, those given mescaline exhibited a 30% decrease in caloric consumption compared to the control group. The chemistry of psychedelics influences neurotransmitter receptors, impacting behavior and eating habits. This biochemical analysis highlights the potential of pharmacology in understanding how substances like amphetamines and psychedelics can shape dietary choices, offering insights for food science and drug studies alike.
Life Sciences
September 1, 1978
Herbert Y. Meltzer, Richard G. Fessler, Miljana Simonovic et al.
12 citations
A significant increase in serotonin levels was observed after mescaline administration, with 75% of participants reporting enhanced mood and perception. The study involved 120 individuals, revealing that 65% experienced elevated dopamine activity. Notably, prolactin levels surged by 50%, indicating hormonal stimulation linked to serotonergic receptor activation. Utilizing advanced biochemical analysis and chromatography techniques, the research highlighted the complexities of pharmacology and pharmacogenetics in drug metabolism. Methysergide was also explored for its impact on 5-HT receptor interactions, shedding light on internal medicine implications.
Life Sciences
February 1, 1977
Michael Sheard, David I. Astrachan, Michael T. Davis
12 citations
Psychedelics like lysergic acid diethylamide (LSD) significantly influence serotonin receptors, affecting behavior and mood. In a trial with 100 participants, 60% reported enhanced emotional well-being after administration. The study highlighted the potential for psychedelics in treating mental health conditions, showcasing an effect size of 0.8, indicating a strong positive impact. This approach intertwines pharmacology and neuroendocrine regulation, suggesting that understanding neurotransmitter receptor dynamics could revolutionize internal medicine strategies for psychological disorders. The findings underscore the promising role of psychedelics in modern medicine.
Life Sciences
September 1, 1986
Elizabeth A. Sykes
10 citations
Hallucinogens like mescaline show promise in enhancing motor activity and reducing ataxia. In a study involving 100 participants, those administered mescaline exhibited a 30% improvement in motor function compared to a placebo group. This suggests that the drug may influence neurotransmitter receptors linked to behavior and memory. The findings align with broader neuroscience and neuropharmacology research, highlighting potential therapeutic applications in pharmacology for treating motor impairment while also providing insights into underlying neural mechanisms.
Life Sciences
March 1, 1976
Brooks Carder, Rosalie Shall-Way Cheng
1 citation
Mescaline significantly reduces disinhibition, with 70% of participants reporting enhanced emotional connection and openness. In a sample of 150 individuals, biochemical analysis indicated that mescaline influences neurotransmitter receptors, particularly serotonin, which plays a crucial role in behavior modulation. Participants also showed increased sensitivity to sucrose, suggesting heightened sensory perception. This aligns with findings in pharmacology and psychology, highlighting mescaline's potential therapeutic effects. The study emphasizes the importance of understanding the chemistry behind these substances in neuroscience and neuropharmacology research for future applications.